
Markus Ruhnke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2774941/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	2.9	4,375
2	Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet, The, 2007, 369, 1519-1527.	6.3	1,185
3	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	4.6	970
4	Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). Clinical Infectious Diseases, 2007, 44, 1289-1297.	2.9	663
5	Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood, 2005, 106, 2641-2645.	0.6	355
6	Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Annals of Hematology, 2018, 97, 197-207.	0.8	162
7	Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (ACIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology, 2014, 93, 13-32.	0.8	143
8	Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses, 2011, 54, 279-310.	1.8	118
9	Advances in the diagnosis and treatment of fungal infections of the CNS. Lancet Neurology, The, 2018, 17, 362-372.	4.9	93
10	Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Annals of Hematology, 2014, 93, 1449-1456.	0.8	88
11	Treatment of fungal infections in hematology and oncology. Annals of Hematology, 2003, 82, S133-S140.	0.8	79
12	Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. Lancet Oncology, The, 2014, 15, e606-e619.	5.1	75
13	Central venous catheter-related infections in hematology and oncology. Annals of Hematology, 2008, 87, 863-876.	0.8	71
14	Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (<scp>AGIHO</scp>). Mycoses, 2018, 61, 796-813.	1.8	69
15	Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. Mycoses, 2007, 50, 196-200.	1.8	59
16	Guideline: Vulvovaginal candidosis (AWMF 015/072, level S2k). Mycoses, 2021, 64, 583-602.	1.8	56
17	Central venous catheter–related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology, 2021, 100, 239-259.	0.8	54

18 Estimated burden of fungal infections in Germany. Mycoses, 2015, 58, 22-28.

MARKUS RUHNKE

#	Article	IF	CITATIONS
19	Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (ACIHO) of the German Society of Hematology and Oncology (DCHO). Mycoses, 2020, 63, 653-682.	1.8	42
20	Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology, 2021, 100, 321-336.	0.8	34
21	Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. Mycoses, 2015, 58, 58-64.	1.8	31
22	Recent developments in the management of invasive fungal infections in patients with oncohematological diseases. Therapeutic Advances in Hematology, 2016, 7, 345-359.	1.1	27
23	Determining the analytical specificity of PCR-based assays for the diagnosis of IA: What is <i>Aspergillus</i> ?. Medical Mycology, 2017, 55, myw093.	0.3	24
24	Interlaboratory comparison of PCRâ€based identification of <i>Candida</i> and <i>Aspergillus</i> DNA in spiked blood samples. Mycoses, 2012, 55, 426-434.	1.8	14
25	Prospective evaluation of the Septi <scp>FAST</scp> multiplex realâ€time <scp>PCR</scp> assay for surveillance and diagnosis of infections in haematological patients after allogeneic stem cell transplantation compared to routine microbiological assays and an inâ€house realâ€time <scp>PCR</scp> method. Mycoses. 2017. 60. 781-788.	1.8	11
26	Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia. Mycoses, 2018, 61, 331-336.	1.8	8
27	First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study. Breast, 2021, 60, 70-77.	0.9	4
28	Clinical Syndromes: Candida and Candidosis. , 2019, , 45-75.		3
29	Infektionen bei Patienten mit hĤnatologisch-onkologischen Erkrankungen. , 2017, , 233-262.		0
30	Infektionen bei Patienten mit hĤnatologisch-onkologischen Erkrankungen. , 2020, , 251-279.		0